How to Calculate Percentage of Weight Loss? Evidence Review (Formula, Examples)

The formula: %TBWL = (Starting weight − Current weight) / Starting weight × 100. Example: 220 lb → 198 lb is (220 − 198) / 220 × 100 = 10.0%. Clinical thresholds: 5% is meaningful per Look AHEAD^[1], 10%+ scales benefit progressively^[2], and 15-21% is the GLP-1 trial magnitude^[3][4].

At a glance

• Formula: %TBWL = (SW − CW) / SW × 100. Unit-agnostic — works in pounds or kilograms as long as both weights use the same unit. Always anchor the denominator to your original starting weight, not a recent weigh-in.
• Worked example (200 lb start): losing 10 lb = 5.0%; losing 20 lb = 10.0%; losing 30 lb = 15.0%; losing 42 lb = 21.0% (the SURMOUNT-1 tirzepatide endpoint^[4]).
• Why percentage, not pounds: a 200 lb person losing 20 lb has lost 10%; a 150 lb person losing the same 20 lb has lost 13.3%. The clinical and trial literature reports everything as %TBWL so comparisons are honest across body sizes.
• 5% threshold is the canonical inflection. Look AHEAD Wing 2011 Diabetes Care^[1] documented meaningful HbA1c, blood pressure, triglyceride, and HDL improvements at ≥5% TBWL in adults with type 2 diabetes.
• Magkos 2016 confirms progressive benefit. Controlled-feeding endpoints at 5%, 11%, and 16% TBWL^[2] showed insulin sensitivity and β-cell function improve at each step.
• GLP-1 magnitude benchmarks. STEP-1 semaglutide 2.4 mg weekly: −14.9% TBWL at 68 weeks^[3]. SURMOUNT-1 tirzepatide 15 mg weekly: −20.9% TBWL at 72 weeks^[4]. These are the mean trial endpoints — your individual result will scatter around them.
• Healthy rate: roughly 1% per month (~0.25% per week) on lifestyle alone; 0.5-1% per week during an active calorie deficit or GLP-1 titration; faster rates are usually water + glycogen, not fat.

The formula explained

The percentage of total body weight loss (%TBWL) is the single number the entire clinical and trial literature uses to report weight outcomes:

%TBWL = (Starting weight − Current weight) / Starting weight × 100

Three things matter:

• The denominator is always your starting weight. This is the original baseline weigh-in at the start of the program — not last month’s weight, not a recent low. Using the current weight as the denominator answers a different question (recent rate) and is not comparable to trial endpoints.
• The numerator is total weight lost. Starting weight minus current weight. Negative numerator means you’ve gained, and the percentage comes out negative.
• Multiply by 100 to get a percent. If you leave the answer as a decimal (0.10), you have the proportion; multiplied by 100 you have the percent (10%). Trials, drug labels, and the Look AHEAD paper all report the percent form.

The formula is unit-agnostic. Pounds give the same percentage as kilograms as long as both weights are in the same unit. Don’t mix units in a single calculation — convert first.

Why percentage and not pounds: the same 20 lb means different things

The reason every weight-loss trial and clinical guideline uses percentage rather than absolute pounds is straightforward. The same 20 lb represents very different magnitudes depending on starting weight:

• 150 lb start → 130 lb: 20 lb lost, 13.3% TBWL.
• 200 lb start → 180 lb: 20 lb lost, 10.0% TBWL.
• 250 lb start → 230 lb: 20 lb lost, 8.0% TBWL.
• 300 lb start → 280 lb: 20 lb lost, 6.7% TBWL.

The metabolic-benefit literature is calibrated to the percentage axis. A 5% TBWL is the Look AHEAD^[1] threshold whether you started at 150 lb or 300 lb — 5% is 5%. Reporting raw pounds without the denominator obscures whether someone has crossed the clinical-benefit line. This is also why GLP-1 trial readouts (STEP-1, SURMOUNT-1, STEP-5, SURMOUNT-4) are all reported as percentages: the mean baseline weight in each trial differs, so absolute pounds wouldn’t be comparable across trials or to clinical targets.

Worked examples across starting weights

Three honest starting points showing how the same %TBWL maps to different absolute pounds:

• 160 lb starting weight. 5% = 8 lb lost (now 152 lb). 10% = 16 lb (now 144 lb). 15% = 24 lb (now 136 lb). 21% = ~34 lb (now ~126 lb — SURMOUNT-1 endpoint).
• 220 lb starting weight. 5% = 11 lb (now 209 lb). 10% = 22 lb (now 198 lb). 15% = 33 lb (now 187 lb). 21% = ~46 lb (now ~174 lb).
• 300 lb starting weight. 5% = 15 lb (now 285 lb). 10% = 30 lb (now 270 lb). 15% = 45 lb (now 255 lb). 21% = ~63 lb (now ~237 lb).

The 5% column is the meaningful-benefit line per Look AHEAD Wing 2011^[1] and the Magkos 2016 Cell Metab controlled-feeding endpoint^[2]. The 15-21% column is GLP-1 trial magnitude per STEP-1^[3] and SURMOUNT-1^[4].

The 5% threshold: where the benefit line starts

The Look AHEAD secondary analysis by Wing, Lang, Wadden, Safford, Knowler, and the Look AHEAD Research Group 2011 Diabetes Care^[1] is the canonical 5% paper. In 5,145 adults with type 2 diabetes randomized to intensive lifestyle intervention vs diabetes support and education, the team found that ≥5% TBWL at 1 year produced clinically meaningful improvements in HbA1c, systolic and diastolic blood pressure, triglycerides, and HDL cholesterol. At 10-15% TBWL, the benefits scaled progressively larger. Below 5%, the cardiometabolic signal was indistinct from baseline noise.

The Magkos, Fraterrigo, Yoshino, and colleagues 2016 Cell Metab controlled-feeding study^[2] measured insulin sensitivity, β-cell function, and adipose tissue biology at three stepwise weight-loss endpoints in 40 adults with obesity: 5%, 11%, and 16%. At 5% TBWL there were already meaningful improvements in insulin sensitivity and β-cell function; additional benefits accrued progressively at 11% and 16%. The 5% inflection isn’t arbitrary — it’s where the metabolic machinery starts to respond.

GLP-1 trial benchmarks: −14.9% and −20.9%

The two GLP-1 reference points that anchor most patient expectations are:

• STEP-1 (Wilding 2021 NEJM^[3]). Semaglutide 2.4 mg subcutaneous weekly in 1,961 adults with overweight or obesity, 68 weeks. Mean weight change −14.9% TBWL on drug vs −2.4% on placebo. This is the Wegovy registration trial.
• SURMOUNT-1 (Jastreboff 2022 NEJM^[4]). Tirzepatide 15 mg subcutaneous weekly in 2,539 adults with obesity, 72 weeks. Mean weight change −20.9% TBWL on drug vs −3.1% on placebo. This is the Zepbound registration trial.

These are mean endpoints — individual patient outcomes scatter widely around them. A reasonable expectation range for a patient completing full titration is roughly −10% to −20% on semaglutide and −15% to −25% on tirzepatide, with about 10-15% of patients classified as non-responders (<5% TBWL by week 17, the standard non-response definition). See our companion piece on the GLP-1 weight-loss timeline for the week-by-week trajectory and our noticeable-weight-loss thresholds piece for when each percentage milestone becomes perceptible to you, your partner, and strangers.

Magnitude check: the %TBWL ladder

Reading the chart honestly: the 5% line is where benefit starts; the 11-16% range is where most non-pharmacological intensive interventions land at 1-2 years; the 14.9-20.9% range is what current GLP-1 pharmacotherapy adds on top. The gap between the 5% line and the GLP-1 endpoint range is the magnitude that nothing pre-2021 could reliably produce outside of bariatric surgery.

Monthly milestones: how fast the percentage should drop

The clinically endorsed rate of weight loss is approximately 0.5-1.0 kg (~1-2 lb) per week during the active phase, which for most adults works out to roughly:

• Lifestyle alone (modest deficit): ~0.25% per week, ~1% per month. Reaching 5% TBWL takes 5-6 months.
• Active calorie deficit (500-1,000 kcal/day): ~0.5-1% per week, ~2-4% per month. Reaching 5% TBWL takes 5-10 weeks; reaching 10% takes 10-20 weeks.
• GLP-1 titration phase (weeks 4-20): ~0.3-0.5% per week is typical. The first 4 weeks of titration usually show ~1-2% TBWL; weeks 8-12 cross the 5% line; weeks 16-20 cross 8-10%.
• GLP-1 plateau phase (weeks 52-72): the curve flattens. Mean STEP-1 weight loss past week 60 added only ~1-2 percentage points to reach the −14.9% endpoint. SURMOUNT-1 likewise flattened toward −20.9%.

Rates above 2% per week are nearly always water and glycogen in the first 1-2 weeks, not fat. After the first month, fat- loss can only mobilize at roughly 3,500 kcal per pound — a hard physiological ceiling. Sustained losses faster than ~1.5% TBWL per week beyond month one tend to indicate either a measurement error, dehydration, or muscle loss alongside fat.

Plateau math: when the percentage stops dropping

Plateaus are biologically real. Metabolic adaptation (the ~5-15% drop in resting energy expenditure that follows meaningful weight loss) plus unconscious intake creep are the two dominant drivers. The math:

• A 200 lb person at maintenance burns roughly 2,400 kcal/day. After 15% TBWL (now 170 lb), maintenance drops to roughly 2,100 kcal/day from body-mass-driven decline alone, plus an additional ~150-250 kcal/day from adaptive thermogenesis — for a total of roughly 1,900 kcal/day to maintain the new weight.
• If the original 500 kcal/day deficit (eating 1,900 kcal/day to burn 2,400) is held constant in absolute calories, the deficit has shrunk to ~0 kcal/day by the time the new maintenance hits 1,900. The scale stops moving.
• A real plateau (3+ weeks of flat 7-day rolling average despite the same effort) is normally remediated by either a deeper deficit, additional protein to preserve lean mass, a diet break, or accepting the new weight as a stable plateau. Adding cardio rarely fixes the math on its own.

How to track: weekly average, not daily fluctuation

The bathroom scale fluctuates 1-4 lb between any two consecutive days from glycogen, water, sodium, stool, and the menstrual cycle — none of which reflect fat compartment change. The honest protocol:

• Weigh daily, same conditions. Morning, fasted, after the bathroom, before coffee or water, no clothes. Record every reading.
• Only look at the 7-day rolling average. The mean smooths the noise. A 7-day mean dropping ~0.5% per week is a working program; flat for 3+ weeks is a real stall.
• Calculate %TBWL weekly, not daily. Use the 7-day mean as the “current weight” in the formula. The percentage moves slowly — that’s the point.
• Track waist circumference monthly. Tape at the navel, fasted, morning. One inch off the waist roughly corresponds to 5% TBWL in most adults and tracks visceral fat reduction more honestly than scale weight during stalls.

Use the GLP-1 weight loss calculator to project weekly %TBWL trajectories on semaglutide, tirzepatide, or oral GLP-1 agents using STEP-1 and SURMOUNT-1 curves, and the GLP-1 BMI calculator to convert a target %TBWL into a projected BMI endpoint.

What NOT to do: don’t compare absolute pounds to other people

The single most common interpretation error in patient forums and social media is comparing absolute pounds across people with different starting weights. “She lost 40 lb in 6 months and I only lost 25 lb in the same time” is not a meaningful comparison without the starting-weight denominator. If she started at 280 lb (40 lb = 14.3%) and you started at 180 lb (25 lb = 13.9%), the percentages are nearly identical — you both crossed the GLP-1 active-phase line, just with different absolute pounds.

Other tracking anti-patterns:

• Using a moving denominator. If you reset the denominator to your weight each month, you’ll show smaller percentages each subsequent month even when progress is identical. Always anchor to original starting weight for the cumulative %TBWL.
• Reading single-day spikes as failures. A 3 lb overnight scale rise is almost certainly water and glycogen from a higher-carb or higher-sodium meal — it will normalize in 24-72 hours. Daily noise is not a fat- gain signal.
• Targeting unrealistic rates. 2 lb per week forever is not physiologically possible past month one. Setting the goal there guarantees a sense of failure even when biology is doing exactly what it should.

For GLP-1 patients: how to interpret your %TBWL during titration

If you’re on semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), or oral orforglipron, anchor your expectations to the trial curves rather than absolute pounds:

• Weeks 0-4 (titration to 0.25-0.5 mg sema or 2.5 mg tirzepatide): ~1-2% TBWL. Mostly water and early appetite suppression. Below the “visible” threshold.
• Weeks 8-12: ~4-6% TBWL on sema; ~6-8% on tirzepatide. Crosses the 5% Look AHEAD^[1] meaningful-benefit line.
• Weeks 16-20: ~8-10% TBWL on sema; ~10-12% on tirzepatide. Others start noticing.
• Week 17 non-response check: <5% TBWL by week 17 is the standard non-response definition. Triggers a clinical conversation about dose adjustment, adherence, or switching agents.
• Weeks 52-72: trial endpoints — mean −14.9% on sema^[3] and −20.9% on tirzepatide^[4]. Individual results scatter widely.

For the side-effect side of the titration arc and how gastrointestinal tolerability shapes your effective rate, see our GLP-1 side effect questions hub.

FAQs

What is the formula for percentage of weight loss?

%TBWL = (Starting weight − Current weight) / Starting weight × 100. Example: a 220 lb start dropping to 198 lb is (220 − 198) / 220 × 100 = 10.0% TBWL. Works in any unit — pounds or kilograms — as long as both weights use the same unit.

Why use percentage instead of pounds lost?

Because absolute pounds mean different things at different starting weights. A 200 lb person losing 20 lb has lost 10% of body weight; a 150 lb person losing the same 20 lb has lost 13.3%. The clinical literature (Look AHEAD Wing 2011 Diabetes Care^[1]; Magkos 2016 Cell Metab^[2]; STEP-1^[3]; SURMOUNT-1^[4]) reports everything as %TBWL because the metabolic-benefit and trial-endpoint comparisons only work on a percentage scale.

What counts as a clinically meaningful percentage?

5% TBWL is the canonical threshold per the Look AHEAD Wing 2011^[1] secondary analysis — the point at which HbA1c, blood pressure, triglycerides, and HDL improve meaningfully in adults with type 2 diabetes. The Magkos 2016 controlled-feeding study^[2] confirmed insulin sensitivity and β-cell function start improving at 5% TBWL, with progressive benefit at 11% and 16%. 10% is the next inflection; 15%+ is GLP-1 magnitude territory.

What is the formula in metric units (kilograms)?

Identical: %TBWL = (Starting kg − Current kg) / Starting kg × 100. The formula is unit-agnostic. A start of 100 kg dropping to 85 kg is (100 − 85) / 100 × 100 = 15.0% TBWL. Don’t mix units in one calculation — convert both sides to the same unit first.

What does Wegovy or Zepbound percentage weight loss mean?

It’s the %TBWL averaged across trial participants vs their baseline weight. STEP-1 semaglutide 2.4 mg weekly produced −14.9% mean TBWL at 68 weeks^[3]. SURMOUNT-1 tirzepatide 15 mg weekly produced −20.9% mean TBWL at 72 weeks^[4]. A 220 lb patient hitting −15% has lost ~33 lb; hitting −20% has lost ~44 lb. Individual results scatter widely around the mean.

How fast should the percentage drop each month?

Roughly 1% per month (about 0.25% per week) is the conservative healthy lifestyle rate. 0.5-1% per week is the active phase of a 500-1,000 kcal/day deficit or early GLP-1 titration. On full-dose semaglutide or tirzepatide most patients average ~0.3-0.5% per week during the active loss phase, then plateau around weeks 52-72. Faster rates (>2% per week) usually reflect water and glycogen loss, not fat.

Should I use my starting weight or my current weight as the denominator?

Always your original starting weight, for cumulative %TBWL. Using the current weight as the denominator (sometimes called “last-month loss”) answers a different question — recent rate, not total progress. The clinical and trial convention is cumulative %TBWL anchored to the first weigh-in.

What if I’ve gained some back — how do I calculate?

Use the same formula against your original starting weight. If you started at 220 lb, hit 180 lb (−18.2% TBWL), then regained to 192 lb, your current %TBWL is (220 − 192) / 220 × 100 = 12.7%. You’ve lost 12.7% from baseline net of regain. Both the nadir (lowest weight) and the current weight matter for clinical follow-up.

Do I weigh myself daily or weekly to track this?

Daily, at the same time (morning, fasted, after bathroom, before coffee or water), and only look at the 7-day rolling average. The bathroom scale fluctuates 1-4 lb per day from glycogen + water + sodium + stool + menstrual cycle — the fat compartment changes slowly underneath. A single daily number is noise; the 7-day mean is the honest readout.

Where do I plug this into a calculator?

Use the WLR GLP-1 weight loss calculator to model expected %TBWL trajectories on semaglutide, tirzepatide, or oral GLP-1 agents using STEP-1 and SURMOUNT-1 curves. Use the GLP-1 BMI calculator to convert %TBWL into a projected BMI endpoint.